News Conference News ESC 2025 NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure Michael O'Riordan September 04, 2025
News Opinion Editor's Corner ESC 2025 What’s Going to Be Hot at ESC Congress 2025? Michael O'Riordan August 25, 2025
News Conference News ESC 2024 Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events Michael O'Riordan September 01, 2024
News Conference News ESC 2023 ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran Michael O'Riordan September 01, 2023
News Conference News ESC 2022 Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE Michael O'Riordan August 31, 2022
News Conference News ESC 2021 New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy Michael O'Riordan September 03, 2021
News Conference News ESC 2021 No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER Michael O'Riordan September 02, 2021
News Conference News ESC 2020 In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD Yael L. Maxwell September 01, 2020
News Conference News ESC 2019 Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories Yael L. Maxwell September 06, 2019
News Conference News ESC 2019 New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL Michael O'Riordan September 05, 2019
News Conference News ESC 2019 ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date Yael L. Maxwell September 03, 2019
News Conference News ESC 2019 Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS Yael L. Maxwell August 31, 2019
News Conference News ESC 2017 Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1 Michael O'Riordan September 05, 2017
News Conference News ESC 2017 Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed Michael O'Riordan August 29, 2017
Presentation ESC 2017 Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial Presenter: Robert Giugliano August 28, 2017
News Conference News ESC 2017 Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab Michael O'Riordan August 28, 2017
News Conference News ESC 2017 CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events Michael O'Riordan August 27, 2017
News Opinion Editor's Corner ESC 2017 ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On Shelley Wood August 18, 2017
News Conference News ESC 2016 Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say Michael O'Riordan August 27, 2016
News Conference News ESC 2015 ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff September 09, 2015